Inclusion Criteria:

          -  All patients must have cytology/ biopsy proven diagnosis of a mullerian carcinoma,
             high clinical index of suspicion for ovarian cancer OR triple negative, BRCA mutated
             breast cancer.

          -  Patients may not have received prior treatment for breast or ovarian cancer.

          -  All patients must be of at least 18 years of age.

          -  ECOG Performance status must be 0,1 or 2.

          -  Patients must not have received a prior PARP inhibitor

          -  Adequate organ and marrow function as defined below:

          -  absolute neutrophil count >/= 1500/mcL

          -  Platelets > /= 100,000 /mcl

          -  Hemoglobin >/= 8 g/dl

          -  Total bilirubin </= 1.5 x the institutional ULN

          -  AST, ALT </= 3 x the institutional ULN

          -  Creatinine </= the institutional ULN

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for
             the duration of study participation, and for 90 days following completion of therapy.
             Should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately.

          -  A female of child-bearing potential is any woman (regardless of sexual orientation,
             having undergone a tubal ligation, or remaining celibate by choice) who meets the
             following criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy; or

               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
                  has had menses at any time in the preceding 12 consecutive months).

          -  Patients must be able to swallow and retain oral medications.

          -  Ability to understand and the willingness to sign a written informed consent.

        Exclusion Criteria:

          -  Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting
             study treatment. Subjects must have recovered from prior treatment-related to
             toxicities to grade 1 or baseline (excluding alopecia and clinically stable toxicities
             requiring ongoing medical management, such as hypothyroidism from prior immune
             checkpoint inhibitor treatment).

          -  Subjects may not be receiving any other investigational agents for the treatment of
             the cancer under study.

          -  Brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Lynparza or other agents used in study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that, in the opinion of the
             investigator, would limit compliance with study requirements.

          -  Subjects must not be pregnant or nursing due to the potential for congenital
             abnormalities and the potential of this regimen to harm nursing infants.